Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Hemostasis and Thrombosis

Background:

• High-dose aprotinin use in cardiac operations is associated with bleeding reduction but carries risks and high costs.
• Investigating lower doses of aprotinin is crucial to balance efficacy with safety and cost-effectiveness.

Purpose of the Study:

• To evaluate the effectiveness of a reduced dose of aprotinin (half the Hammersmith regimen) in mitigating bleeding during cardiac surgery.
• To assess the impact of this low-dose aprotinin on blood fibrinolysis parameters and postoperative bleeding.

Main Methods:

• A double-blind, placebo-controlled study involving 40 elective coronary artery bypass grafting patients.
• Measurement of fibrinolysis markers (tissue plasminogen activator, plasminogen activator inhibitor, alpha 2-antiplasmin, D-dimer), platelet count, bleeding times, and aprotinin levels pre-, intra-, and post-operation.

Main Results:

• Aprotinin significantly inhibited fibrinolysis, indicated by decreased D-dimer and tissue plasminogen activator levels, and increased plasminogen activator inhibitor and alpha 2-antiplasmin levels.
• The placebo group experienced a 38% higher incidence of abnormal postoperative bleeding times (p < 0.05).
• Achieved adequate aprotinin plasma concentrations for effective inhibition of plasmin and plasma kallikrein.

Conclusions:

• Half-dose aprotinin effectively inhibits fibrinolysis in cardiac surgical patients.
• This reduced dosage prevents abnormal postoperative bleeding times, suggesting a potentially safer and more cost-effective therapeutic option.